PreS was selected as the carrier protein for these allergy vaccines because it contains the binding site of HBV to its cognate receptor NTCP on liver cells, and hence was expected to generate antibodies upon immunization that may also protect against HBV infections. This evidence concerns the gene SLC26A5 and allergic disease.